Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis

A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC)

The research aims to evaluate the efficacy and safety of that mesalazine with hydrocortisone sodium succinate for the induction of clinical remission during a 4-week double-blind treatment period in active UC (define as total Mayo score of greater than or equal to 4 and less than or equal to 10). A total of 528 patients will be randomly divided into three group, one will receive mesalazine 4g with hydrocortisone sodium succinate 100mg enema, and the other two group will respectively to receive mesalazine 4g and hydrocortisone sodium 100mg one times daily for 4 weeks. The end of the study for every patient is the improvement of main symptoms.The primary endpoint is the clinical remission after 2 and 4 weeks double-blind treatment, defined on the basis of a total Mayo score ≤ 2 points, with no subscore > 1 point. The secondary endpoint are endoscopic mucosal healing at week 2 and 4 of double-blind period, defined as an absolute subscore for endoscopy portion of the Mayo score of 0 point and the change from baseline in Quality of Life at week 4 of double-blind period based on the IBDQ.

Study Overview

• Status: Unknown
• Conditions: Ulcerative Colitis, Unspecified
• Intervention / Treatment: Drug: Mesalazine with hydrocortisone sodium succinate; Drug: Mesalazine; Drug: hydrocortisone sodium succinate

• Study Type: Interventional
• Enrollment (Anticipated): 528
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Jie Liang, Professor; Phone Number: 86-029-85771535; Email: liangjie@fmmu.edu.cn

Study Locations

• China
  • Shaanxi
    • Xi'an, Shaanxi, China, 710032
      • Recruiting
      • Xijing Digestive Disease
      • Contact: Jie liang, professor; Phone Number: 86-029-84771535; Email: liangjie@fmmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female Chinese patients aged ≥18 to ≤ 70 years
2. Newly diagnosed or recurrent active ulcerative colitis (A gold standard for the diagnosis of ulcerative colitis is not available. The diagnosis should be established by a combination of medical history, clinical evaluation, and typical endoscopic and histological findings. An infective cause should be excluded. Where there is doubt about the diagnosis, endoscopic and histological confirmation is necessary after an interval.)
3. Extent of colonic involvement and endoscopy subscore of Mayo score as confirmed by colonoscopy (it should be done within 15 days prior to randomization)
4. Total Mayo score of at least 4 and a score of ≥ 2 for colonoscopy
5. Oralthe stability dose of 5-ASA medicine 14days.
6. Negative stool test at screening to rule out parasites and bacterial pathogens
7. The patient is compliant with Patient Daily Diary
8. Women with childbearing potential must have an efficacious contraception as judged by the investigators and must have a negative pregnancy test result at screening
9. Signed Informed Consent obtained before any trial-related procedures.

Exclusion Criteria:

1. Severe/fulminant ulcerative colitis or toxic dilatation of the colon
2. Prior bowel resection surgery
3. Known infection of human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV) (Note active Hepatitis B patients should be excluded from the study e.g. HBeAg positive or HBV DNA positive, with the exception for inactive HBsAg carrier)

4. Take the following treatment:

   1. Any 5-ASA enema or suppository therapy during the 14 days prior to screening
   2. Corticosteroids (oral, intravenous, intramuscular, or rectal ) within 7 days prior to screening
   3. Any immunomodulating/suppressive agents during the 60 days prior to screening
   4. Any Anti-TNF therapy during the 6 months prior to screening
   5. Antibiotics (metronidazole and ciprofloxacin) within 7 days prior to screening
   6. Loperamide, nicotine patch and mucilages within 7 days prior to screening
   7. Traditional Chinese Medicine for the treatment of UC (any pharmaceutical form) within 7 days prior to screening
5. Patients allergic to 5-ASA and derivative, any of the excipients, aspirin, or salicylates
6. Known significant hepatic function abnormalities, defined as the values of serum ALT or AST are equal to or more than twice of the upper limit of normal value
7. Women who are planning or actual pregnancy or lactation during study period
8. Alcohol addiction (>40 g of alcohol/day equivalent to >1 L of beer/day, 0.5 L of wine/day, or 6 glasses (2 centiliter, cl) of liquor/day)
9. Drug addiction confirmed by patients' medical history
10. History of disease that would interfere with their participation in the trial, including malignant diseases, bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, and mental or emotional disorder
11. Patient participating or having participated in another clinical study 30 days prior to screening
12. Patient who are unlikely to comply with the protocol as judged by the investigator
13. Patients who are unable to fill in the Patient Daily Diary or follow data-capturing procedures
14. Patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and Crohn's disease
15. Patients with any other disease or condition which might interfere with study assessment as judged by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Mesalazine with hydrocortisone sodium succinate; Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema	Drug: Mesalazine with hydrocortisone sodium succinate; Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
Active Comparator: Mesalazine; Mesalazine （4g）enema	Drug: Mesalazine; Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
Active Comparator: Hydrocortisone sodium succinate; Hydrocortisone sodium succinate (100mg ) enema	Drug: hydrocortisone sodium succinate; hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of clinical remission	Clinical remission after 2 and 4 weeks double-blind treatment, defined on the basis of a total Mayo score ≤ 2 points, with no subscore > 1 point	2 weeks, 4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of endoscopic mucosal healing	endoscopic mucosal healing at week 2 and 4 of double-blind period, defined as an absolute subscore for endoscopy portion of the Mayo score of 0 point	2 weeks, 4 weeks
Change of quality of life based on the IBDQ	The change from baseline in Quality of Life at week 2 and 4 of double-blind period based on the IBDQ	2 weeks, 4 weeks
Change of mental health by Anxiety and Depression Assessment Scale	Assess mental health by Anxiety and Depression Assessment Scale	2 weeks, 4 weeks

Collaborators and Investigators

• Sponsor: Xijing Hospital of Digestive Diseases
• Collaborators: Shanghai Tongji Hospital, Tongji University School of Medicine; First Affiliated Hospital of Zhongshan Medical University
• Investigators: Principal Investigator: jie Liang, professor, China,Shaanxi,Xi'an, Xijing Hospital of Digeetive Disease

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2017
• Primary Completion (Anticipated): January 1, 2018
• Study Completion (Anticipated): March 1, 2018

Study Registration Dates

• First Submitted: February 19, 2017
• First Submitted That Met QC Criteria: April 6, 2017
• First Posted (Actual): April 12, 2017

Study Record Updates

• Last Update Posted (Actual): April 12, 2017
• Last Update Submitted That Met QC Criteria: April 6, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Keywords: Mesalazine; Ulcerative Colitis(UC); Enema
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Gastrointestinal Diseases; Gastroenteritis; Colonic Diseases; Intestinal Diseases; Inflammatory Bowel Diseases; Ulcer; Colitis; Colitis, Ulcerative; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Mesalamine
• Other Study ID Numbers: KY20162063-1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No